Antimicrobial peptides are ancient components of innate immunity found across species. Two research compounds dominate this space: LL-37 (a cathelicidin) and KPV (a tripeptide fragment of α-MSH). Both are studied for antimicrobial, anti-inflammatory, and wound-healing research contexts.
LL-37 is the sole cathelicidin in humans — a 37-amino-acid antimicrobial peptide cleaved from the hCAP18 precursor. It is expressed by neutrophils, epithelial cells, and macrophages as part of the innate immune response. Research has examined its direct antimicrobial activity against bacteria, fungi, and enveloped viruses, plus a broad range of immunomodulatory effects.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH). Research has shown that this short fragment retains much of the anti-inflammatory activity of full α-MSH — including effects on NF-κB signaling — while being smaller and more stable than the parent peptide.
| Attribute | LL-37 | KPV |
|---|---|---|
| Size | 37 amino acids | 3 amino acids |
| Origin | Human cathelicidin (hCAP18 cleavage) | α-MSH C-terminal fragment |
| Primary mechanism | Direct antimicrobial + immunomodulatory | Anti-inflammatory via NF-κB modulation, melanocortin pathway |
| Research focus | Infection, biofilms, innate immunity | Inflammation (especially gut), wound healing |
| Stability | Protease-sensitive, requires careful handling | More stable due to smaller size |
LL-37 is studied for antimicrobial activity (bacteria, fungi, enveloped viruses in vitro), biofilm disruption research, wound healing, and immunomodulation. It is the sole cathelicidin in humans and plays a central role in innate immunity. Research also examines its complex role in autoimmune conditions where elevated LL-37 is associated with disease (psoriasis, lupus models).
KPV's antimicrobial effects in research are primarily indirect — via anti-inflammatory and immunomodulatory pathways rather than direct bacterial killing. It is classified more accurately as an anti-inflammatory peptide with innate-immunity-modulating effects. Full α-MSH has more direct antimicrobial activity; KPV retains the anti-inflammatory portion of the signaling.
KPV's NF-κB pathway modulation and small size (three amino acids) make it well-suited for gut mucosa research. Preclinical IBD models (TNBS-induced colitis, DSS-induced colitis) have shown KPV reduces inflammation markers. The small size also suggests oral administration routes in research models.
Yes — their mechanisms are complementary. LL-37 provides direct antimicrobial and neutrophil-chemotactic signaling; KPV provides anti-inflammatory resolution signaling. Some research protocols combine them when studying both phases of the innate immune response.
Yes. LL-37 and KPV are legal to acquire for research purposes in the United States. They are classified as research-use-only compounds — not for human consumption. Licensed researchers and physicians may acquire them for preclinical research and practice-of-medicine use.
Every SMART MD batch is verified by three independent U.S. laboratories — HPLC purity, mass spectrometry, LAL endotoxin. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify before purchase.
Check the documentation before you order.